SYDNEY, AUSTRALIA – August 21, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €1,221,906 (~ A$1,910,010) cash rebate from the French Government under its Cre´dit d’Impo^t Recherche scheme (CIR).
The “Cre´dit d’Impo^t Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
For further information please download PDF attached:
Download this document
